Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M

seekingalpha2021-11-11

Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

BubbleGumbo
2021-11-11
BubbleGumbo
[Miser] [Miser]
ALAL
2021-11-11
ALAL
Ok
- ALAL:
  Great
- BubbleGumbo:
  [What][What]
- Ahleepapa:
  Gd
- siewbee:
  K
alv
2021-11-11
alv
Ok
- alv:
  Ok
CalvinYeo
2021-11-11
CalvinYeo
Like
- Snowranger:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1144726166?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-11 20:31","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1144726166","market":"us","top_or_hot":-1,"title":"Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M","media":"seekingalpha","content":"<div>\n<p>Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OGN","symbol_name":"Organon & Co","start_time":0,"source_url":"https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m","article_id":"1144726166","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144726166","pubTimestamp":1636633893,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exc","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OGN":"Organon & Co"},"translate_title":"Organon缩小2021年的指导范围；同意以9.54亿美元收购Forendo Pharma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":0.9},"content_text":"Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance.\nFor the quarter, the topline dipped ~1% YoY to $1.6B after ~5% YoY growth recorded in the previous quarter.\nThe contraction was led by established brands which brought ~$1.0B in sales posting a ~6% YoY decline. Meanwhile, women’s health and biosimilars recorded $381M and $140M in sales with a ~10% YoY decline and ~41% YoY growth, respectively.\nRevenue from the U.S. dropped ~7% YoY to $346M. China and Europe/ Canada brought $252M and $410M sales, posting ~12% YoY growth and ~4% YoY decline, respectively.\nMeanwhile, the gross margin narrowed to ~62% from ~63% in the previous quarter and ~67% in Q3 2020.\nThe net income contracted ~41% YoY to $323M as SG&A expenses climbed ~21% YoY to $388M.\nFor 2021, Organon (OGN) has revised its guidance for revenue and adjusted EBITDA margin to $6.2B - 6.3B and 36.5%-37.5% from $6.1B-$6.4B and 36%-38% estimated three months ago, respectively.\nSeparately, the company announced an agreement to acquire Forendo Pharma, a clinical-stage pharma company focused on women’s health, for a total consideration of $954M. The transaction is expected to close in December 2021.\nSince its trading began in mid-May, Organon (OGN) has outperformed the broader market with over 10% gain YTD, as shown in the graph below.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":870528325,"gmtCreate":1636636326821,"gmtModify":1636636327178,"author":{"id":"3582966792980858","authorId":"3582966792980858","name":"BubbleGumbo","avatar":"https://static.tigerbbs.com/3ea67ad05fa0074d870d9c061d20bf79","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582966792980858","authorIdStr":"3582966792980858"},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870528325","repostId":1144726166,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":870582305,"gmtCreate":1636634271177,"gmtModify":1636634271493,"author":{"id":"3573967796529092","authorId":"3573967796529092","name":"ALAL","avatar":"https://static.tigerbbs.com/875b16da8a8772902d1aaf69f6c0d98a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573967796529092","authorIdStr":"3573967796529092"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/870582305","repostId":1144726166,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6607302,"gmtCreate":1637108404907,"gmtModify":1637108404933,"authorId":3573967796529092,"author":{"id":3573967796529092,"idStr":"3573967796529092","authorId":3573967796529092,"name":"ALAL","avatar":"https://static.tigerbbs.com/875b16da8a8772902d1aaf69f6c0d98a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870582305,"type":1,"supId":0,"prevId":0,"content":"Great","text":"Great","html":"Great"},{"id":6538326,"gmtCreate":1636636322415,"gmtModify":1636636322448,"authorId":3582966792980858,"author":{"id":3582966792980858,"idStr":"3582966792980858","authorId":3582966792980858,"name":"BubbleGumbo","avatar":"https://static.tigerbbs.com/3ea67ad05fa0074d870d9c061d20bf79","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870582305,"type":1,"supId":0,"prevId":0,"content":"[What][What]","text":"[What][What]","html":"[What][What]"},{"id":6537994,"gmtCreate":1636634346134,"gmtModify":1636634390673,"authorId":3585038405943602,"author":{"id":3585038405943602,"idStr":"3585038405943602","authorId":3585038405943602,"name":"Ahleepapa","avatar":"https://static.tigerbbs.com/dcc1fea9c38112b58c68a2d96017330b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870582305,"type":1,"supId":0,"prevId":0,"content":"Gd","text":"Gd","html":"Gd"},{"id":6537987,"gmtCreate":1636634282707,"gmtModify":1636634282802,"authorId":3572672230120758,"author":{"id":3572672230120758,"idStr":"3572672230120758","authorId":3572672230120758,"name":"siewbee","avatar":"https://static.tigerbbs.com/aecff165cb101c9c535379b2947e2cbe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870582305,"type":1,"supId":0,"prevId":0,"content":"<u>K</u>","text":"<u>K</u>","html":"<u>K</u>"}],"langContent":"CN"},{"id":870586272,"gmtCreate":1636634213330,"gmtModify":1636634213645,"author":{"id":"3554847271592222","authorId":"3554847271592222","name":"alv","avatar":"https://static.tigerbbs.com/bb02b26030f8c7529c746ee2157620b3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554847271592222","authorIdStr":"3554847271592222"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870586272","repostId":1144726166,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6537986,"gmtCreate":1636634273476,"gmtModify":1636634273505,"authorId":3554847271592222,"author":{"id":3554847271592222,"idStr":"3554847271592222","authorId":3554847271592222,"name":"alv","avatar":"https://static.tigerbbs.com/bb02b26030f8c7529c746ee2157620b3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870586272,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":870586970,"gmtCreate":1636634121892,"gmtModify":1636634161538,"author":{"id":"3577186064735986","authorId":"3577186064735986","name":"CalvinYeo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3577186064735986","authorIdStr":"3577186064735986"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870586970","repostId":1144726166,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6537963,"gmtCreate":1636634142781,"gmtModify":1636634142821,"authorId":3582013295209832,"author":{"id":3582013295209832,"idStr":"3582013295209832","authorId":3582013295209832,"name":"Snowranger","avatar":"https://static.tigerbbs.com/dfac7c612eed065a985994d454b7693a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":870586970,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":44,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144726166"}